Background: The potential of a defined microbial therapy

A randomized, controlled phase 1b trial comparing the 15-strain live biotherapeutic MTC01 with fecal microbiota transplantation (FMT) from the same donor in patients with recurrent Clostridioides difficile infection (rCDI) was published in Nature Medicine. At eight weeks after treatment, recurrence had been prevented in 7 of 9 patients in the MTC01 group and 8 of 9 in the FMT group. Safety was the primary endpoint, and no treatment-related adverse events were reported in any of the four treatment groups.

FMT is an effective treatment for rCDI, but its microbial composition is not clearly defined and scaling up production is difficult. Live biotherapeutic products (LBPs) manufactured ex vivo offer an approach in which strain composition can be defined and production scaled up. The researchers noted, however, that manufacturing is more complex and few such products have advanced to clinical trials.

This study directly compared same-donor FMT with MTC01, a 15-strain product manufactured ex vivo. A distinguishing feature was that both approaches were based on strains from the same donor, allowing the researchers to examine clinical outcomes and intestinal engraftment.

Key findings: Safety and eight-week recurrence prevention assessed in 18 patients

Of 20 screened patients, the research team randomized the 18 who met eligibility criteria into four groups: 4 received low-dose FMT, 5 high-dose FMT, 4 low-dose MTC01, and 5 high-dose MTC01. The overall female-to-male ratio was reported as 5:1.

According to the abstract, the primary safety endpoint was met. Ten adverse events occurred in 8 patients, with 5 events each reported among patients receiving MTC01 and FMT. No adverse events were reported as treatment-related in any of the four groups. This is distinct from saying that no adverse events occurred. The abstract provided does not detail the event types or severity, limiting a more specific assessment of safety.

Efficacy and strain engraftment were secondary endpoints. At eight weeks after treatment, recurrence prevention was observed in 7/9 patients in the MTC01 group and 8/9 in the FMT group; the researchers described the outcomes as similar. These figures alone do not establish statistical equivalence or noninferiority between the treatments. The outcome assessed was prevention of rCDI recurrence at that time point, not general symptom improvement.

High and sustained intestinal engraftment of strains was reported with both treatments. A dose-related engraftment effect was also observed with MTC01, but the abstract did not provide specific engraftment rates, duration, or effect sizes by dose. Strain engraftment in the gut should be distinguished from the clinical outcome of preventing recurrence.

Meaning and outlook: Sharing manufacturing materials and early clinical evidence

The researchers said they are providing a platform for manufacturing LBPs for clinical trials, along with regulatory documents and manufacturing protocols. These materials offer a reference for taking products with defined strain compositions into patient studies. They may inform subsequent LBP development, but the abstract did not report results measuring whether manufacturing complexity was reduced or approval timelines shortened.

This was an early study involving 18 patients overall, with 9 per treatment. Larger studies and longer follow-up will be needed to assess differences in recurrence prevention and to examine rare adverse events or long-term safety. The current findings provide early evidence for further evaluation of MTC01; it is premature to interpret them as establishing a replacement for FMT or patient-specific strain therapy.

Source: Article abstract and bibliographic information indexed in Europe PMC.